Jump to navigation

Draft pandemic treaty could force Big Pharma to share vaccines with developing countries

Major battles lie ahead as negotiations on a new treaty to set rules for production and distribution of life-saving drugs

Negotiations on protocols for a global and national level pandemic response have started with the World Health Organization's (WHO) Intergovernmental Negotiating Body's (INB) publication of a 'zero-draft' of a new pandemic treaty last week.

The draft states that the WHO is 'deeply concerned by the gross inequities' of supply, production and access to Covid-19 vaccines. Its proposal to reserve at least 20% of any tests, vaccines or treatments for use in poorer countries is likely to prompt major pushback from pharmaceutical giants.

Civil society groups say the treaty should compel governments to commit to sharing medical technology and knowhow. It also states that the intellectual property rules that uphold pharmaceutical company monopolies must be waived automatically when a health emergency is declared.

This points to the need for clear enforcement of the treaty which raises another raft of diplomatic questions. The WHO insists the treaty should be legally binding.

The draft cites the backdrop to its recommendations as the 'catastrophic failure of the international community in showing solidarity and equity in response to the novel Covid-19 pandemic'. The final draft is set to be presented at the World Health Assembly in 2024.

Other proposals in the draft include strengthening and sustaining capacities of health systems, cooperation for sustainable and predictable financing, and raising pandemic and public health literacy for pandemic prevention, preparedness, response and recovery.

It also calls for the establishment of the WHO Global Pandemic Supply Chain and Logistics Network to promote production and transfer of technology and know-how.

This network would boost research and development capacities and establish a Pathogen Access Benefit-Sharing System (PABS) to ensure equitable and timely sharing of pathogens with pandemic potential and genomic sequences.



Related Articles

Who will buy?

Barely 12 months ago there was real urgency in efforts to develop Covid-19 vaccine production facilities in Africa, and even United States President Joe Biden backed some kind...


The pandemic's collateral damage

The focus on the coronavirus, coupled with logistical problems, is drawing resources from the fight against Africa’s other serious diseases

Covid-19 is serious enough, but in Africa the unintended consequences of diverting health service resources may be even worse. 'The knock-on effects of Covid-19 on the fight against...


Flying flu

The next six weeks are crucial in Africa for the much-feared spread of avian influenza, which may be carried by birds migrating from affected countries in central Asia...


A scramble for vaccines

Despite pious pledges of equal access to the shots, Africa is losing out. Fixing that will take more cooperation and bold policy

While the outgoing chair of the African Union, South Africa's President Cyril Ramaphosa, was able to make a triumphant announcement on 13 January that the AU had 'secured'...


Fatigue may be fatal

Africa's health ministers watch with alarm the disastrous fatality rate as the second wave of the virus rips across India

The Covid-19 experience in Africa has been something of a rollercoaster ride. Early predictions were calamitous, then it seemed to pass ominously mildly (unless you were in South...